In a clinical trial of 67 pediatric patients with persistent or chronic ITP...

62% of patients (28 of 45) reached their target platelet level, some as early as Week 1

 

 

In a clinical trial of 92 pediatric patients with chronic ITP...

of patients (26 of 63) maintained a response for at least 6 weeks

 

 

13%of patients (6 of 45) on PROMACTA® (eltrombopag) needed to take rescue medication to raise their platelet levels compared with 50% of patients (11 of 22) on placebo
  • In a second study, 19% (12 of 63) on PROMACTA needed rescue medication versus 24% (7 of 29) on placebo

 

53%of patients (8 of 15) taking other ITP medications were able to reduce or stop using them after starting PROMACTA
  • In a second study, 46% of patients (6 of 13) taking PROMACTA reduced or stopped other ITP medications

Patients with ITP prefer once-daily oral dosing

The ITP World Impact Survey (I-WISh) was a global survey conducted in 13 countries with 1507 patients and 472 physicians. In the US alone, there were more than 500 patients. The survey asked about patient preference for administration. Here’s what it found:

 

  • Most patients, 87%, said they prefer treatment that could be taken by mouth once a day (over an injectable therapy or a twice-daily oral regimen)